ALVO

アフターアワーズ： 5.95 0.08 +1.36%

Alvotech (ALVO)

概要ニュース株価時系列ディスカッション予測

Relative Volume:

ネットキャッシュフロー:

Alvotech Stock (ALVO) Company Profile

Healthcare (1065)

ALVO's Discussions on Twitter

Compare ALVO vs TAK, TEVA, HLN, ZTS, UTHR

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
ALVO Alvotech	5.87	1.89B	563.46M	27.92M	-146.33M	0.0964
TAK Takeda Pharmaceutical Co Adr	18.91	58.31B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	38.98	43.22B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.28	40.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.40	30.15B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	494.63	21.32B	3.17B	1.29B	1.01B	27.09

Alvotech Stock (ALVO) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2025-12-09	開始されました	Barclays	Underweight
2025-11-04	ダウングレード	Deutsche Bank	Buy → Hold
2025-10-14	アップグレード	Morgan Stanley	Equal-Weight → Overweight
2025-09-23	アップグレード	Deutsche Bank	Hold → Buy
2025-02-14	開始されました	UBS	Buy
2024-01-29	アップグレード	Barclays	Equal Weight → Overweight
2023-10-20	アップグレード	Citigroup	Sell → Neutral
2023-09-21	開始されました	Barclays	Equal Weight
2022-09-07	開始されました	Morgan Stanley	Equal-Weight
2022-09-06	ダウングレード	Citigroup	Buy → Sell
2022-07-26	開始されました	Citigroup	Buy

Alvotech (ALVO) 最新ニュース

Alvotech (ALVO) 財務データ

Alvotech (ALVO)

Alvotech Stock (ALVO) Company Profile

Compare ALVO vs TAK, TEVA, HLN, ZTS, UTHR

Alvotech Stock (ALVO) Upgrades & Downgrades

Alvotech (ALVO) 最新ニュース

What Is Putting Alvotech Stock in Focus? (NASDAQ:ALVO) - Kalkine Media

Citadel Advisors LLC Makes New $6.38 Million Investment in Alvotech $ALVO - MarketBeat

Understanding the Setup: (ALVO) and Scalable Risk - Stock Traders Daily

Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st

Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com

Alvotech’s Subcutaneous Biosimilar Vedolizumab BLA Accepted for Review by FDA - Pearce IP

Alvotech (NASDAQ:ALVO) Shares Up 5.4%Here's What Happened - MarketBeat

FDA to review Alvotech (Nasdaq: ALVO) subcutaneous Entyvio biosimilar - stocktitan.net

Alvotech Says FDA Accepted Biologics License Application for AVT80 - marketscreener.com

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations - Yahoo Finance

Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed? - simplywall.st

Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical - Yahoo Finance

Alvotech (ALVO) Stock Still Trades At A Discount After A 57% Rally - simplywall.st

Bank of America sees major upside in this biotech stock - Yahoo Finance

Alvotech to present at upcoming investor conferences in September - Yahoo Finance

Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - simplywall.st

Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update - Sahm

ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Moomoo

Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom

Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes - Pulse 2.0

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT) - The Globe and Mail

Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey

Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media

Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha

Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma

Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci

Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan

Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com

Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com

Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan

Alvotech Q2 2026 Earnings Call Transcript - Sahm

Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st

Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail

Alvotech holds rating despite H1 2026 earnings miss and FDA delays, eyes multiple biosimilar approvals by Q4 2026. - Pluang

Alvotech earnings missed by $0.02, revenue fell short of estimates - Investing.com India

Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts (ALVO) - Seeking Alpha

Alvotech (NASDAQ:ALVO) Trading 6.8% HigherHere's What Happened - MarketBeat

Alvotech Q2 Earnings Call Highlights - MarketBeat

Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls - Investing.com

ALVO: Revenue and margins set to rebound in H2 as supply normalizes and portfolio expands - TradingView

Alvotech Q2 2026 Earnings Call Summary - Yahoo Finance

Alvotech Provides Earnings Guidance for the Full Year 2026 - marketscreener.com

Alvotech 1H Adjusted EBITDA $46.9 M >ALVO - Moomoo

Alvotech (ALVO) reports Q2 loss, beats revenue estimates - FXStreet

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Iceland's Alvotech H1 revenue falls 31% on manufacturing program - TradingView

Alvotech (NASDAQ:ALVO) Releases Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat

Alvotech Q2 Results: EPS Misses Estimate, Sales Fall 39% YoY - scanx.trade

Alvotech (ALVO) 財務データ

収益

当期純利益

現金流量

EPS

ALVOに似た銘柄